focus -WSS

focus

author：leisure time 2025-08-12 09:09:21 - browse：62649

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Why you shouldn’t ask, “What country has the best health care?”

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Why the world’s most expensive drug might be worth the price

Medicare drug price negotiation legal challenge met with skepticism

Merck drug for rare lung condition set for approval in U.S.

Boston competes with Raleigh

States should stop sabotaging methadone treatment reform

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Alkermes shareholders re

10 reasons why health care startups fail

Affirmative action in medical school literally saved lives

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

In Memoriam: Notable people who died in 2023

Merck drug for rare lung condition set for approval in U.S.

Wikipedia

There's no autism epidemic. It's an autism diagnosis epidemic

Abortion pill Supreme Court ruling could impact entire drug industry

Steward Health Care has deal to sell doctor network to UnitedHealth

States should stop sabotaging methadone treatment reform

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Patient advocates debate FDA's accelerated approval process

knowledge

focus

hotspot

knowledge